Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research report released on Wednesday. The brokerage issued a sell rating on the stock.

Oragenics Stock Down 6.3 %

Shares of NYSE OGEN opened at $0.17 on Wednesday. The firm has a market capitalization of $3.62 million, a P/E ratio of -0.02 and a beta of 1.16. The stock’s 50-day simple moving average is $0.22 and its two-hundred day simple moving average is $0.28. Oragenics has a twelve month low of $0.16 and a twelve month high of $3.43.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.